Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

  title={Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention},
  author={Borwin Bandelow and Dirk Wedekind and Teresa Le{\'o}n},
  journal={Expert Review of Neurotherapeutics},
  pages={769 - 781}
Pregabalin is the first anxiolytic pharmacologic alternative for the treatment of generalized anxiety disorder (GAD) to be introduced in more than 10 years. GAD is a significant psychiatric condition with lifetime prevalence rates ranging between 5.7 and 6.4%. It causes significant impairment in quality of life and functional abilities equivalent to those associated with major depression. Randomized, controlled trials confirm that pregabalin is superior to placebo and comparable with lorazepam… 

Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder

Pregabalin (Lyrica®), a well established anxiolytic agent, has been approved in the EU for the treatment of generalized anxiety disorder (GAD) in adults and is considered a first-line agent for the long-term treatment of GAD by the World Federation of Societies of Biological Psychiatry.

Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature

A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.

Pregabalin versus sertraline in generalized anxiety disorder. An open label study.

This investigation showed that pregabalin, an atypic anxiolytic is efficient and well tolerable in treatment of GAD and showed good results in treating symptoms of Generalized Anxious Disorder.

Generalized Anxiety Disorder in Adults: Focus on Pregabalin

Pregabalin is a novel structural analogue of the inhibitory neurotransmitter GABA, acting to reduce calcium ion flow through the α2δ subunit of pre-synaptic voltage-dependent calcium channels, which has low abuse potential.

A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder

  • M. Boschen
  • Psychology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2011
Pregabalin is an efficacious therapy for GAD, although effect sizes are smaller than those from earlier studies.

Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder

Pregabalin is an alternative compound to SSRIs and SNRIs for the first-line treatment of generalized anxiety disorder (GAD) and its favorable pharmacokinetic properties are all favorable for the treatment of GAD patients, including those with comorbid depressive symptoms or medical conditions.

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

Evidence from available randomized placebo-controlled as well as head-to-head clinical trials with other drugs regarding its efficacy and safety in the GAD treatment is evaluated.

Efficacy and safety of pregabalin in the treatment of alcohol and benzodiazepine dependence

Monotherapy with pregabalin, within the dosage range of 150 – 600 mg/d, is a promising “novel” option for the safe and efficacious relapse prevention of both AD and BD, however, its efficacy in the acute treatment of AD withdrawal syndrome is still controversial.

Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study.

This study does not support the usefulness of adding pregabalin in patients with GAD and UMD and with an early nonresponse to escitalopram.

Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis

Patient-level data were pooled from nine phase II and III randomized, double-blind, short-term, placebo-controlled trials of pregabalin for the treatment of GAD to determine those predictive of clinical improvement at endpoint.



Pregabalin for the treatment of generalised anxiety disorder

  • S. Montgomery
  • Psychology, Medicine
    Expert opinion on pharmacotherapy
  • 2006
Pregabalin was effective in more or less severe G AD, on psychic and somatic symptoms of GAD, and in treating the subsyndromal depressive symptoms in the elderly and the effect on cognitive function was minimal and notably less than that observed with benzodiazepines.

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.

Pregabalin was safe, well tolerated, and rapidly efficacious across the physical-somatic as well as the emotional symptoms of GAD in the majority of patients studied in primary care and psychiatric settings.

Pregabalin in generalized anxiety disorder: a placebo-controlled trial.

Pregabalin is an effective, rapidly acting, and safe treatment for generalized anxiety disorder in short-term treatment and does not appear to have the withdrawal symptoms associated with the benzodiazepines.

Pregabalin: in the treatment of generalised anxiety disorder.

Oral pregabalin, typically at dosages of 300-600 mg/day, was superior to placebo and similar to lorazepam, alprazolam and venlafaxine in improving anxiety and depressive symptoms in patients with moderate-to-severe generalised anxiety disorder (GAD).

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.

Pregabalin was significantly more efficacious than placebo for the treatment of psychic and somatic symptoms of generalized anxiety disorder and was well tolerated by most study patients.

Evidence-based pharmacotherapy of Generalized Anxiety Disorder.

Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative.

Escitalopram in the treatment of generalized anxiety disorder

Escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.

Long-term efficacy of pregabalin in generalized anxiety disorder

The study indicates that pregabalin is an effective treatment for the prevention of relapse in patients with GAD.

Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder

Clinically important differences were noted between drugs in the onset of effect, with alprazolam producing rapid and sustained improvement within the first week of treatment and buspirone producing more gradual, continuous improvement throughout the study.

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam.

The results of the study need replication, but suggest a potentially important role for antidepressants, particularly imipramine, in patients suffering from GAD.